Description
Capan-1 is a human pancreatic ductal adenocarcinoma cell line. These cells grow in adherent tissue culture and display epithelial morphology. In culture, these cells are capable of invading through an extracellular matrix, such as Matrigel. The Capan-1 cells are resistant to 5-fluorouracil, reminiscent of the original tumor from which they were derived. They form poorly-differentiated tumors when injected into immunocompromised mice. These cells harbor a single base-pair deletion in the BRCA2 allele, which results in the expression of a truncated and dysfunctional protein. In addition, they have an oncogenic mutation in K-Ras (G12V) and an inactivating mutation in p53. These cells express elevated levels of the Epidermal Growth Factor Receptor (EGFR) and do not express SMAD4 protein (i.e., SMAD4-null). The Capan-1 cells are useful both as a xenograft model for pancreatic cancer and as a cell system to study the effects of BRCA2-deficiency.
Source
This cell line was established in 1974 from a metastatic site (liver) in a 40-year-old Caucasian male with pancreatic ductal adenocarcinoma.
Inventors
Jorgen Fogh, PhD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering
Key References
- Fogh J et al. (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. Journal of the National Cancer Institute 59: 221-226 (PubMed ID: 327080)
- Kyriazis AP et al. (1982) Human pancreatic adenocarcinoma line Capan-1 in tissue culture and the nude mouse: morphologic, biologic, and biochemical characteristics. American Journal of Pathology 106: 250-260 (PubMed ID: 6278935)
- Deer EL et al. (2010) Phenotype and genotype of pancreatic cancer cell lines. Pancreas 39: 425-435 (PubMed ID: 20418756)
Licensing Information
This cell line may be licensed nonexclusively for research or commercial purposes.
- Express License: For internal research purposes by a for-profit entity: 1) Fill out MSK’s ATCC Express License, see here for links to the online fillable ATCC Express License, as well as a PDF version. 2) After execution by MSK, you will receive a signed copy, and can then place your order with ATCC. For detailed guidance on how to fill out this webform, see here. Please note: In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. This license is only available for select cell lines, including this one. Once this license has been executed by MSK, you will receive a signed copy and payment instructions; all payments up to $10,000 must be made by credit card.
- Commercial License: Contact MSK’s Tangible Materials team at [email protected].
For non-licensing requests from academic-research institutions: Contact Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, [email protected].